Canada Pension Plan Investment Board Sells 54,100 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Canada Pension Plan Investment Board lowered its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 94.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,400 shares of the company's stock after selling 54,100 shares during the period. Canada Pension Plan Investment Board's holdings in Omnicell were worth $151,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Sumitomo Mitsui Trust Group Inc. boosted its position in Omnicell by 93.3% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock worth $64,573,000 after purchasing an additional 699,925 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Omnicell by 32.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock worth $67,951,000 after purchasing an additional 377,883 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Omnicell by 79.3% in the fourth quarter. Renaissance Technologies LLC now owns 456,343 shares of the company's stock worth $20,316,000 after buying an additional 201,831 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Omnicell by 46.1% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 429,687 shares of the company's stock valued at $19,130,000 after buying an additional 135,650 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Omnicell during the fourth quarter valued at approximately $5,372,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on OMCL shares. Bank of America cut their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research report on Monday, January 6th. Wells Fargo & Company reduced their price target on Omnicell from $40.00 to $38.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. StockNews.com raised Omnicell from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. JPMorgan Chase & Co. decreased their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Finally, Benchmark reiterated a "buy" rating and issued a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $50.67.

Omnicell Price Performance

OMCL traded up $0.24 during trading on Thursday, reaching $31.50. 222,835 shares of the company traded hands, compared to its average volume of 534,729. The company has a market cap of $1.48 billion, a P/E ratio of 116.65, a PEG ratio of 7.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.75. The firm has a fifty day simple moving average of $33.80 and a 200 day simple moving average of $40.63.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.